U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Russia Stocks End Flat as Energy and Retail Shares Show Mixed Performance 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Asian Stocks Slip as Oracle Earnings Miss Sparks AI Profitability Concerns 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Oil Prices Edge Higher as U.S. Seizes Sanctioned Venezuelan Tanker 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Fed’s Dovish Tone Sends Dollar Lower as Markets Price In More Rate Cuts 
Japan Weighs New Tax Breaks to Boost Corporate Investment Amid Spending Debate 
Medipost Co. Ltd, a South Korean biotechnology company, purchased a stake in Canada's OmniaBio Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), as it is planning to launch its own contract development and manufacturing organization (CDMO) business in North America.
Medipost Co. is planning to make new stem cell treatment products at OmniaBio's facilities in Canada. Thus, it entered into a strategic agreement with the company that is currently a leader in stem cell therapeutics in the world.
The Korean firm engages in the development and manufacturing of stem cell biotech products, and it has acquired a 39.6% stake in OmniaBio Inc. Mediapost is putting in an investment of ₩29.5 billion or around $30 million in Canadian dollars for the purchase. The acquisition deal is set to close on July 1.
According to The Korea Economic Daily, Medipost will be establishing its CDMO business in North America after the deal is completed. It is also planning to raise its stake in OmniaBio by buying convertible bonds worth ₩59.1 billion, and the company is hoping to achieve this by the end of 2024.
With the given numbers, Medipost is set to become the Canadian CDMO firm's largest shareholder, with the total investment reaching C$90 million. OmniaBio's facility is located in Hamilton, Ontario, and it is currently working on a project to expand its facilities for cell and gene therapies from 8,500 square meters to 10,000 square meters site by the year 2025.
"CCRM has spent a great deal of time looking for the right investment partner for OmniaBio, and we are very pleased to have Medipost on board," OmniBio's president, Mitchel Sivilotti, said in a press release. "Medipost will be an initial anchor and revenue generating customer of OmniaBio and will also help us develop an international customer base in Asia. We are launching from a strong and stable position and will be starting construction at McMaster Innovation Park this summer."
Finally, it was revealed that the money from Medipost's purchase deal will be used for the real estate construction and operation of OmniaBio. The overall project was said to be worth $580 million.
